Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted Revenue of $215.4 million for Q1 2026, down 11.65% sequentially from $243.8 million in Q4 2025, and up 16.59% YoY from $184.7 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Revenue for 7 years, with the latest figure at $215.4 million in Q1 2026.
- Quarterly Revenue rose 16.59% year-over-year to $215.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $899.1 million (up 20.71% YoY) and the FY2025 annual result came in at $868.5 million, up 21.51% from the prior year.
- Revenue eased to $215.4 million in Q1 2026 per HRMY's latest filing, from $243.8 million in the prior quarter.
- Over five years, Revenue peaked at $243.8 million in Q4 2025 and troughed at $85.3 million in Q1 2022.
- A 5-year average of $165.8 million and a median of $168.4 million in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2025: Revenue jumped 45.18% in 2022, then gained 16.01% in 2025.
- Over 5 years, Revenue stood at $128.3 million in 2022, then soared by 31.26% to $168.4 million in 2023, then rose by 19.51% to $201.3 million in 2024, then advanced by 21.12% to $243.8 million in 2025, then dropped by 11.65% to $215.4 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $215.4 million, $243.8 million, and $239.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 261.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 261.28 Mn |
| Mar 31, 2026 | 215.39 Mn |
| Dec 31, 2025 | 243.78 Mn |
| Sep 30, 2025 | 239.46 Mn |
| Jun 30, 2025 | 200.49 Mn |
| Mar 31, 2025 | 184.73 Mn |
| Dec 31, 2024 | 201.27 Mn |
| Sep 30, 2024 | 186.04 Mn |
| Jun 30, 2024 | 172.81 Mn |
| Mar 31, 2024 | 154.62 Mn |
| Dec 31, 2023 | 168.41 Mn |
| Sep 30, 2023 | 160.27 Mn |
| Jun 30, 2023 | 134.22 Mn |
| Mar 31, 2023 | 119.13 Mn |
| Dec 31, 2022 | 128.31 Mn |
| Sep 30, 2022 | 117.21 Mn |
| Jun 30, 2022 | 107.03 Mn |
| Mar 31, 2022 | 85.31 Mn |
| Dec 31, 2021 | 91.21 Mn |
| Sep 30, 2021 | 80.73 Mn |